Significant Ownership of Kynam Capital Management, LP

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for Kynam Capital Management, LP focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
Yue Tang - Managing Member
Manager location
Princeton, NJ

Follow Filing Activity

Follow Kynam Capital Management, LP and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Significant Ownership of Kynam Capital Management, LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BNR Burning Rock Biotech Ltd American Depository Shares ("ADSs") of the Issuer, each ADS representing one Class A Ordinary Share, par value $0.0002 per share 14% 0 -100% Kynam Capital Management, LP 31 Mar 2026
SNDX Syndax Pharmaceuticals Inc Common Stock, par value $0.0001 per share 10% $113,571,600 8,520,000 Kynam Capital Management, LP 31 Dec 2024
CLDX Celldex Therapeutics, Inc. Common Stock, par value $0.001 8.8% $0 -$203,190,000 0 -100% Kynam Capital Management, LP 31 Mar 2026
CTMX CytomX Therapeutics, Inc. Common Stock, $0.00001 par value per share 6.9% $0 -$38,554,131 0 -100% Kynam Capital Management, LP 31 Mar 2026
VERA Vera Therapeutics, Inc. Class A common stock, $0.001 par value per share 5.4% $83,444,698 3,426,887 Kynam Capital Management, LP 30 Jun 2025
CGEM Cullinan Therapeutics, Inc. Common Stock, par value $0.0001 per share 5.3% $37,245,019 3,114,132 Kynam Capital Management, LP 31 Dec 2025
STRO Sutro Biopharma, Inc. Common stock, $0.001 par value 5.3% $0 0 Kynam Capital Management, LP 31 Mar 2026
DVAX DYNAVAX TECHNOLOGIES CORP Common Stock, par value $0.001 per share 5% $71,513,102 6,560,835 Kynam Capital Management, LP 31 Dec 2024
COGT Cogent Biosciences, Inc. Common Stock, par value $0.001 4.3% $219,296,982 -$61,214,156 6,165,223 -22% Kynam Capital Management, LP 31 Dec 2025
ENGN enGene Holdings Inc. Common Shares, no par value per share 2.2% $12,510,485 -$29,339,989 1,492,898 -70% Kynam Capital Management, LP 31 Dec 2025
VRDN Viridian Therapeutics, Inc. Common Stock, $0.01 par value 1.5% $46,689,677 +$46,689,677 1,470,541 Kynam Capital Management, LP 31 Dec 2025
TSVT 2seventy Bio, Inc. Common Stock, par value $0.0001 per share 0% $0 0 Kynam Capital Management, LP 11 Mar 2025

Schedules 13D/G Reported by Kynam Capital Management, LP:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .